NasdaqGS - Nasdaq Real Time Price • USD
Design Therapeutics, Inc. (DSGN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.26 | -0.28 | -1.17 | -1.4 |
| Low Estimate | -0.31 | -0.35 | -1.49 | -1.7 |
| High Estimate | -0.23 | -0.24 | -0.97 | -1.22 |
| Year Ago EPS | -0.35 | -0.36 | -1.19 | -1.17 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.36 | -0.4 | -0.41 | -0.31 |
| EPS Actual | -0.35 | -0.36 | -0.28 | -0.21 |
| Difference | 0.01 | 0.04 | 0.13 | 0.1 |
| Surprise % | 2.80% | 10.00% | 31.70% | 32.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.26 | -0.28 | -1.17 | -1.4 |
| 7 Days Ago | -0.27 | -0.29 | -1.18 | -1.36 |
| 30 Days Ago | -0.27 | -0.29 | -1.18 | -1.36 |
| 60 Days Ago | -0.33 | -0.34 | -1.4 | -1.35 |
| 90 Days Ago | -0.33 | -0.34 | -1.4 | -1.35 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DSGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.70% | -- | -- | 5.40% |
| Next Qtr. | 22.20% | -- | -- | 10.90% |
| Current Year | 1.70% | -- | -- | 4.50% |
| Next Year | -19.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/20/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 3/20/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 11/14/2023 |
| Downgrade | Wedbush: Outperform to Neutral | 8/15/2023 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 8/15/2023 |
| Downgrade | RBC Capital: Outperform to Sector Perform | 8/15/2023 |
Related Tickers
IKNA Ikena Oncology, Inc.
1.3000
-0.76%
VOR Vor Biopharma Inc.
1.6900
-0.59%
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
BRNS Barinthus Biotherapeutics plc
2.5000
-1.57%
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
HOWL Werewolf Therapeutics, Inc.
6.75
+8.70%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%
LYEL Lyell Immunopharma, Inc.
2.1700
-1.36%
FENC Fennec Pharmaceuticals Inc.
9.21
+0.55%